Neurotransmitters

Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors

Retrieved on: 
Tuesday, August 3, 2021
Science, Biotechnology, Research, Hardware, Oncology, Health, Technology, Clinical trials, Branches of biology, Cancer, Biology, Glutamate carboxypeptidase II, Molecular neuroscience, Neurotransmitters, Proteases, Prostate cancer, MCRPC, Advanced Accelerator Applications, Prostvac, PSMA, prostate cancer and other solid tumors, Ambrx, PSMA, PROSTATE CANCER AND OTHER SOLID TUMORS, AMBRX

The Phase 1 trial will be a multi-center, open-label, dose escalation and dose expansion study.

Key Points: 
  • The Phase 1 trial will be a multi-center, open-label, dose escalation and dose expansion study.
  • The trial will enroll up to 76 patients with advanced solid tumors whose diseases have failed prior standard therapies.
  • While non-ADC therapies are available to treat mCRPC, there is no approved therapy specifically targeting PSMA to treat prostate cancer.
  • Ambrx undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.

Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC

Retrieved on: 
Tuesday, July 20, 2021
Branches of biology, Psychoactive drugs, Neurochemistry, NMDA receptor antagonists, Glutamate, Ionotropic glutamate receptors, Neurotransmitters, NMDA receptor, N-Methyl-D-aspartic acid, Ketamine

Arbormentis LLC is also eligible to receive a low single digit royalty on any commercialized therapy resulting from this agreement.

Key Points: 
  • Arbormentis LLC is also eligible to receive a low single digit royalty on any commercialized therapy resulting from this agreement.
  • Arbormentis LLC is a privately-held drug discovery company engaged in potentially transformative innovations for CNS diseases.
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Poxel Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases Following Recent Achievements

Retrieved on: 
Monday, July 12, 2021
Research, Diabetes, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Medical specialties, Hepatitis, Branches of biology, Clinical medicine, Adenosine monophosphate, Neurotransmitters, Nucleotides, Purines, Steatohepatitis, Non-alcoholic fatty liver disease, NASH, ALD, Poxel SA, NASH, ALD, POXEL SA

Following our recent achievements and a thorough review of the Companys programs, we are excited to announce a new strategic direction for Poxel, with an increasing focus on rare metabolic indications that represents the intersection of high unmet medical needs, promising pre-clinical and clinical data, opinion leader enthusiasm, significant commercial opportunity, and attractive time horizons.

Key Points: 
  • Following our recent achievements and a thorough review of the Companys programs, we are excited to announce a new strategic direction for Poxel, with an increasing focus on rare metabolic indications that represents the intersection of high unmet medical needs, promising pre-clinical and clinical data, opinion leader enthusiasm, significant commercial opportunity, and attractive time horizons.
  • In parallel with the Companys efforts in ALD, another important goal is to launch an additional rare disease development program in 2022.
  • Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders.
  • Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases.

PreveCeutical Files International Patent Application for its Dynorphin Peptides

Retrieved on: 
Wednesday, July 7, 2021
Opioids, Psychoactive drugs, Drugs, Morphine, Euphoriants, Morphinans, Opioid peptides, Neurotransmitters, Dynorphin, Dyn, Pain management, Heroin

Vancouver, British Columbia--(Newsfile Corp. - July 7, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed an International PCT application on July 1, 2021, entitled "Peptides and uses thereof", application number PCT/AU2021/050707 with the aim of seeking protection for certain peptides and their use in pain management.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - July 7, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed an International PCT application on July 1, 2021, entitled "Peptides and uses thereof", application number PCT/AU2021/050707 with the aim of seeking protection for certain peptides and their use in pain management.
  • The International patent application is to protect the dynorphin peptide research that appears to show the most potential for further development as an alternative therapeutic agent to the current opioids, such as morphine, in the management of pain.
  • PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
  • For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook .

NeRRe Therapeutics raises £20 million in a Series B2 financing round

Retrieved on: 
Wednesday, July 7, 2021
Branches of biology, Neuropeptides, Neurotransmitters, Chronic cough, Cough, Tachykinin peptides, Idiopathic pulmonary fibrosis

Stevenage, UK, 7 July 2021 NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, today announces it has raised an additional 20 million in a Series B2 financing round.

Key Points: 
  • Stevenage, UK, 7 July 2021 NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, today announces it has raised an additional 20 million in a Series B2 financing round.
  • The proceeds from the financing round will primarily be used to fund the Phase 2 clinical development of orvepitant as a treatment for chronic cough associated with IPF.
  • NeRRe Therapeutics is a clinical-stage company developing orvepitant, a neurokinin(NK)-1 receptor antagonist, as a first in class, once daily breakthrough treatment for cough hypersensitivity disorders.
  • Fountain Healthcare Partners is a life science focused venture capital fund with EUR 300 million (USD 354 million) under management.

NeRRe Therapeutics raises £20 million in a Series B2 financing round

Retrieved on: 
Wednesday, July 7, 2021
Branches of biology, Neuropeptides, Neurotransmitters, Chronic cough, Cough, Tachykinin peptides, Idiopathic pulmonary fibrosis

Stevenage, UK, 7 July 2021 NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, today announces it has raised an additional 20 million in a Series B2 financing round.

Key Points: 
  • Stevenage, UK, 7 July 2021 NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, today announces it has raised an additional 20 million in a Series B2 financing round.
  • The proceeds from the financing round will primarily be used to fund the Phase 2 clinical development of orvepitant as a treatment for chronic cough associated with IPF.
  • NeRRe Therapeutics is a clinical-stage company developing orvepitant, a neurokinin(NK)-1 receptor antagonist, as a first in class, once daily breakthrough treatment for cough hypersensitivity disorders.
  • Fountain Healthcare Partners is a life science focused venture capital fund with EUR 300 million (USD 354 million) under management.

The Phase 3 ONWARD™ Trial Meets its Screening Target and Nears Enrollment Completion

Retrieved on: 
Tuesday, July 6, 2021
Branches of biology, Neuroscience, Amphetamine, Psychiatric diagnosis, Neurotransmitters, TAAR1 agonists, Serotonin, Attention deficit hyperactivity disorder

The ONWARD trial is evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes.

Key Points: 
  • The ONWARD trial is evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes.
  • We are on track to deliver trial data in the first quarter of 2022, said Schuyler Vinzant, Adials Vice President of Development.
  • The ramifications for all addictions, and even other mental health disorders, could be powerful and significant.
  • Patients are genetically screened prior to enrollment in the ONWARD trial so that only genetically positive patients are enrolled.

Bright Minds Biosciences to Present at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond

Retrieved on: 
Friday, June 11, 2021
Branches of biology, Neuroscience, Neurotransmitters, Psychedelic drugs, Hallucinations, Entheogens, Serotonin receptor agonist, Serotonin, Psilocybin, Serotonergic

The presentation will be webcast beginning at the aforementioned time and available for 7 days thereafter using the link provided above.

Key Points: 
  • The presentation will be webcast beginning at the aforementioned time and available for 7 days thereafter using the link provided above.
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Bright Minds Biosciences to Present at the 2021 LD Micro Invitational XI

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Neuroscience, Neurotransmitters, Psychedelic drugs, Hallucinations, Entheogens, Serotonin receptor agonist, Serotonin, Psilocybin, Serotonergic

The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.

Key Points: 
  • The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline in Prostate Cancer

Retrieved on: 
Thursday, June 3, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, Biology, Glutamate carboxypeptidase II, Molecular neuroscience, Neurotransmitters, Peptidase, Prostate cancer, Accurin, Targeted Alpha Therapies (TAT) at Bayer, Prostate Cancer at Bayer, Xofigo® (radium Ra 223 dichloride) Injection, NUBEQA® (darolutamide)3, Bayer, Noria Therapeutics (Noria) / PSMA Therapeutics Inc., TARGETED ALPHA THERAPIES (TAT) AT BAYER, PROSTATE CANCER AT BAYER, XOFIGO® (RADIUM RA 223 DICHLORIDE) INJECTION, NUBEQA® (DAROLUTAMIDE)3, BAYER, NORIA THERAPEUTICS (NORIA) / PSMA THERAPEUTICS INC.

Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc.

Key Points: 
  • Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc.
  • Prostate cancer is the second most commonly diagnosed cancer in men1 and a key area of focus for Bayer.
  • About Noria Therapeutics (Noria) / PSMA Therapeutics Inc.
    Noria is a research and development company managed by experienced radiopharmaceutical development leaders and focused on the development of novel targeted alpha therapeutics and theranostic agents.
  • PSMA Therapeutics Inc. is a subsidiary of Noria to advance the platform of prostate-specific membrane antigen (PSMA) targeting radiotherapeutics.